PMID- 29261028
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2045-8932 (Print)
IS  - 2045-8940 (Electronic)
IS  - 2045-8932 (Linking)
VI  - 8
IP  - 1
DP  - 2018 Jan-Mar
TI  - The new frontiers of the targeted interventions in the pulmonary vasculature: 
      precision and safety (2017 Grover Conference Series).
PG  - 2045893217752329
LID - 10.1177/2045893217752329 [doi]
LID - 2045893217752329
AB  - The pulmonary vasculature plays an important role in many lung pathologies, such 
      as pulmonary arterial hypertension, primary graft dysfunction of lung transplant, 
      and acute respiratory distress syndrome. Therapy for these diseases is quite 
      limited, largely due to dose-limiting side effects of numerous drugs that have 
      been trialed or approved. High doses of drugs targeting the pulmonary vasculature 
      are needed due to the lack of specific affinity of therapeutic compounds to the 
      vasculature. To overcome this problem, the field of targeted drug delivery aims 
      to target drugs to the pulmonary endothelial cells, especially those in 
      pathological regions. The field uses a variety of drug delivery systems (DDSs), 
      ranging from nano-scale drug carriers, such as liposomes, to methods of 
      conjugating drugs to affinity moieites, such as antibodies. These DDSs can 
      deliver small molecule drugs, protein therapeutics, and imaging agents. Here we 
      review targeted drug delivery to the pulmonary endothelium for the treatment of 
      pulmonary diseases. Cautionary notes are made of the risk-benefit ratio and 
      safety-parameters one should keep in mind when developing a translational 
      therapeutic.
FAU - Brenner, Jacob S
AU  - Brenner JS
AD  - 1 14640 Pulmonary, Allergy, & Critical Care Division, University of Pennsylvania, 
      Philadelphia, PA, USA.
FAU - Kiseleva, Raisa Yu
AU  - Kiseleva RY
AUID- ORCID: 0000-0001-8065-3551
AD  - 2 14640 Department of Pharmacology, The Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA, USA.
FAU - Glassman, Patrick M
AU  - Glassman PM
AD  - 2 14640 Department of Pharmacology, The Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA, USA.
FAU - Parhiz, Hamideh
AU  - Parhiz H
AD  - 2 14640 Department of Pharmacology, The Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA, USA.
FAU - Greineder, Colin F
AU  - Greineder CF
AD  - 2 14640 Department of Pharmacology, The Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA, USA.
FAU - Hood, Elizabeth D
AU  - Hood ED
AD  - 2 14640 Department of Pharmacology, The Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA, USA.
FAU - Shuvaev, Vladimir V
AU  - Shuvaev VV
AD  - 2 14640 Department of Pharmacology, The Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA, USA.
FAU - Muzykantov, Vladimir R
AU  - Muzykantov VR
AD  - 2 14640 Department of Pharmacology, The Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA, USA.
LA  - eng
GR  - K08 HL130430/HL/NHLBI NIH HHS/United States
GR  - K08 HL138269/HL/NHLBI NIH HHS/United States
GR  - T32 HL007439/HL/NHLBI NIH HHS/United States
GR  - T32 HL007954/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20171220
PL  - United States
TA  - Pulm Circ
JT  - Pulmonary circulation
JID - 101557243
PMC - PMC5768280
OTO - NOTNLM
OT  - ARDS
OT  - acute respiratory distress syndromes and acute lung injury
OT  - drug delivery
OT  - endothelium
OT  - inflammation
OT  - vascular targeting
EDAT- 2017/12/21 06:00
MHDA- 2017/12/21 06:01
PMCR- 2017/12/20
CRDT- 2017/12/21 06:00
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2017/12/21 06:01 [medline]
PHST- 2017/12/21 06:00 [entrez]
PHST- 2017/12/20 00:00 [pmc-release]
AID - 10.1177_2045893217752329 [pii]
AID - 10.1177/2045893217752329 [doi]
PST - ppublish
SO  - Pulm Circ. 2018 Jan-Mar;8(1):2045893217752329. doi: 10.1177/2045893217752329. 
      Epub 2017 Dec 20.